Paper6135926
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.
Baum M and 11 others. Lancet, 1983. Cited by 86 papers, by iCite.
Cite this record
ConductScience Library. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Papers, record 6135926. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6135926
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Mastectomy | Major topic |
| Tamoxifen | Major topic |
| Female | |
| Humans | |
| Postoperative Care |
Source PubMed
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41474498 | Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41474498 | PubMed |
| 35626053 | Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626053 | PubMed |
| 34398352 | Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. | Breast Cancer Res Treat | 2021 | https://conductscience.org/library/papers/34398352 | PubMed |
| 33825840 | Estimated Projection of US Cancer Incidence and Death to 2040. | JAMA Netw Open | 2021 | https://conductscience.org/library/papers/33825840 | PubMed |
| 28323900 | Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells. | PLoS One | 2017 | https://conductscience.org/library/papers/28323900 | PubMed |
| 27986463 | Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. | Cancer Lett | 2017 | https://conductscience.org/library/papers/27986463 | PubMed |
| 26346768 | Roles for miRNAs in endocrine resistance in breast cancer. | Endocr Relat Cancer | 2015 | https://conductscience.org/library/papers/26346768 | PubMed |
| 26278220 | Progress in adjuvant chemotherapy for breast cancer: an overview. | BMC Med | 2015 | https://conductscience.org/library/papers/26278220 | PubMed |
| 26052034 | The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. | Mol Cell Endocrinol | 2015 | https://conductscience.org/library/papers/26052034 | PubMed |
| 24980775 | Lost in translation: can we afford to miss the trees for the forest? | Horm Cancer | 2014 | https://conductscience.org/library/papers/24980775 | PubMed |
| 24659478 | Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. | Endocr Relat Cancer | 2014 | https://conductscience.org/library/papers/24659478 | PubMed |
| 22042792 | Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. | Cancer Res | 2011 | https://conductscience.org/library/papers/22042792 | PubMed |
| 22017761 | Male breast carcinoma: increased awareness needed. | Breast Cancer Res | 2011 | https://conductscience.org/library/papers/22017761 | PubMed |
| 18068350 | Tamoxifen: catalyst for the change to targeted therapy. | Eur J Cancer | 2008 | https://conductscience.org/library/papers/18068350 | PubMed |
| 16455026 | Selection of optimal adjuvant endocrine therapy for early-stage breast cancer. | Curr Treat Options Oncol | 2006 | https://conductscience.org/library/papers/16455026 | PubMed |
| 15931325 | NSABP breast cancer clinical trials: recent results and future directions. | Clin Med Res | 2003 | https://conductscience.org/library/papers/15931325 | PubMed |
| 12497042 | Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer? | Prostate Cancer Prostatic Dis | 2001 | https://conductscience.org/library/papers/12497042 | PubMed |
| 10463904 | Contribution of randomised controlled trials to understanding and management of early breast cancer. | BMJ | 1999 | https://conductscience.org/library/papers/10463904 | PubMed |
| 6696816 | Prospects for the future in the management of carcinoma of the breast: the biological fall out from clinical trials. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6696816 | PubMed |
| 6381024 | Current status of chemotherapy of breast cancer. | Drugs | 1984 | https://conductscience.org/library/papers/6381024 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6135926
GET https://conductscience.org/api/papers/v1/6135926/cited_by?page=2